J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
0091270007305299v1
47/10/1222    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ries, M.
Right arrow Articles by Schiffmann, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ries, M.
Right arrow Articles by Schiffmann, R.

BIOLOGICS

Enzyme Replacement in Fabry Disease: Pharmacokinetics and Pharmacodynamics of Agalsidase Alfa in Children and Adolescents

Markus Ries, MD, MHSc, Joe T. Clarke, MD, PhD, Catharina Whybra, MD, Atul Mehta, MD, Kenneth S. Loveday, PhD, Roscoe O. Brady, MD, Michael Beck, MD and Raphael Schiffmann, MD

From the Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland (Dr Ries, Dr Brady, Dr Schiffmann); The Hospital for Sick Children, Toronto, Canada (Dr Clarke); Center for Lysosomal Storage Diseases, Children's Hospital, University of Mainz, Mainz, Germany (Dr Whybra, Dr Beck); Royal Free Hospital, London, United Kingdom (Dr Mehta); and Research, Shire HGT, Cambridge, Massachusetts (Dr Loveday). Dr Ries's current affiliation is Shire HGT, Cambridge, Massachusetts. Dr Loveday's current affiliation is Altus Pharmaceuticals, Cambridge, Massachusetts.

This multicenter, open-label study evaluated pharmacokinetics, pharmacodynamics, and safety of agalsidase alfa in pediatric compared with adult patients with Fabry disease. The pharmacokinetic parameters of pediatric patients (19 boys, 5 girls, 6-18 years old; mean age, 11.8 years) were compared to those of adult male and female patients who participated in other clinical studies. All patients received agalsidase alfa at a dose of 0.2 mg/kg infused over 40 minutes every other week. Agalsidase alfa exhibited a biphasic serum elimination profile with a maximum serum concentration at the end of the 40-minute infusion; <1% of the maximum concentration was detected 8 hours after dosing. In children, serum clearance was 2.0 to 9.4 mL/min/kg and tended to decrease with increasing age. The average clearance in children, 3.7 ± 1.5 mL/min/kg (mean ± SD), was significantly greater than that measured in 33 adults (2.3 ± 0.7 mL/min/kg, P < .0001). Mean terminal elimination half-life of agalsidase alfa was prolonged in week 25 compared with baseline (150 vs 66 minutes) in 8 of 19 male children. The magnitude of the reduction of plasma globotriaosylceremide was similar in all age groups and was independent of area under the curve and other pharmacokinetic parameters. Except for clearance in younger patients, agalsidase alfa appears to have comparable pharmacokinetic and pharmacodynamic profiles in pediatric and adult Fabry patients of both genders.

Key Words: Fabry disease • lysosomal disorders • enzyme replacement therapy

Address for correspondence: Dr Raphael Schiffmann, National Institutes of Health, Building 10, Room 3D03, 9000 Rockville Pike, Bethesda, MD 20892-1260; e-mail: RS4e{at}nih.gov.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American College of Clinical Pharmacology